The global atherosclerosis drugs market size reached USD 48.40 Billion in 2021 and is expected to register a revenue CAGR of 2.5% during the forecast period, according to latest analysis by Emergen Research. An increase in the prevalence of atherosclerosis & cardiovascular diseases is the main factor driving the revenue growth of the atherosclerosis drugs market. Globally, the number of cardiovascular disease-related deaths and disabilities has been continuously increasing over the past 30 years. The illness, which includes heart disease and stroke, was to blame for a startling one-third of all fatalities globally in 2019. In the United States alone, heart disease is the leading cause of death for both sexes and members of the majority of racial and ethnic groups. Cardiovascular disease claims one life in the United States every 34 seconds. In the United States, heart disease claimed the lives of almost 697,000 individuals in 2020, accounting for 1 in 5 fatalities. Between 2017 and 2018, heart disease cost the USD 229 billion annually. This covers the price of prescription drugs, healthcare services, and lost income from deaths.
The report also offers estimations and predictions about the market segment and sub-segments exhibiting promising growth in the forecast timeline. The report also provides deeper insights into the technological advancements, industrial landscape, and emerging product and technological developments in the Atherosclerosis Drugs market. It offers fruitful insights into the business sphere to help businesses capitalize on the lucrative growth opportunities.
Request a Sample Report with Table of Contents and Figures to click Here: https://www.emergenresearch.com/request-sample/1300
Competitive Terrain:
The section on the competitive landscape offers valuable and actionable insights related to the business sphere of the Atherosclerosis Drugs market, covering extensive profiling of the key market players. The report offers information about market share, product portfolio, pricing analysis, and strategic alliances such as mergers and acquisitions, joint ventures, collaborations, partnerships, product launches and brand promotions, among others. The report also discusses the initiatives taken by the key companies to combat the impact of the COVID-19 pandemic.
The leading market contenders listed in the report are:
Sanofi, Hoffmann La-Roche Ltd, Bayer AG, Merck & Co., Inc., Pfizer Inc., Novartis AG, GSK plc, Janssen Global Services, LLC, Amgen Inc., Mylan N.V.
Click to access the Report Study, Read key highlights of the Report and Look at Projected Trends: https://www.emergenresearch.com/industry-report/atherosclerosis-drugs-market
Emergen Research has segmented the global Atherosclerosis Drugs market on the basis of type, application, end-use, and region:
Segments Covered in this report are:
-
Drug Class Outlook (Revenue, USD Billion; 2019-2030)
- Statins
- Fibrates
- Vitamins
- Others
-
Medication Outlook (Revenue, USD Billion; 2019-2030)
- Cholesterol Lowering Medication
- Beta Blockers
- Calcium Channel Blockers
- Diuretics
- Others
-
Distribution Channel Outlook (Revenue, USD Billion; 2019-2030)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
The various regions analyzed in the report include:
- North America (U.S., Canada)
- Europe (U.K., Italy, Germany, France, Rest of EU)
- Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)
- Latin America (Chile, Brazil, Argentina, Rest of Latin America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)
Key Objectives of the Report:
- Analysis and estimation of the Atherosclerosis Drugs Market size and share for the projected period of 2022-2030
- Extensive analysis of the key players of the market by SWOT analysis and Porter’s Five Forces analysis to impart a clear understanding of the competitive landscape
- Study of current and emerging trends, restraints, drivers, opportunities, challenges, growth prospects, and risks of the global Atherosclerosis Drugs Market
- Analysis of the growth prospects for the stakeholders and investors through the study of the promising segments
- Strategic recommendations to the established players and new entrants to capitalize on the emerging growth opportunities
Request Customization as per your specific requirement@ https://www.emergenresearch.com/request-history/1300
Latest Published Reports by Emergen Research: